


hPGDS-IN-1

Cat. No.:	HY-12791		
CAS No.:	1234708-04-3		
Molecular Formula:	C ₂₂ H ₂₀ N ₆ O ₃		
Molecular Weight:	416.43		
Target:	PGE synthase		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 30 mg/mL (72.04 mM; Need ultrasonic and warming)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4014 mL	12.0068 mL	24.0136 mL
	5 mM	0.4803 mL	2.4014 mL	4.8027 mL
	10 mM	0.2401 mL	1.2007 mL	2.4014 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.IC50 value: 12 nM Target: hPGDSThe detailed information please refer to WO2011044307A1 and WO2010080563A2

CUSTOMER VALIDATION

- bioRxiv. 2023 Oct 8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic

and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.

[2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.

[3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA